Form 4: BioXcel Director Mack Granted 17,000 Stock Options

BioXcel Therapeutics Director David J. Mack was granted 17,000 stock options with an exercise price of $2.01, vesting based on service.

Summary

• David J. Mack, a Director of BioXcel Therapeutics, Inc. (BTAI), was granted 17,000 stock options.
• The transaction date for this grant was January 9, 2026.
• Each option has an exercise price of $2.01.
• The options will vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the grant date, contingent on Mr. Mack's continued service as a non-employee director.
• The options have an expiration date of January 9, 2036.
• Following this transaction, Mr. Mack beneficially owns 17,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.

Future Outlook

The stock options are subject to a vesting schedule, becoming exercisable on the earlier of the first anniversary of the grant date or the day prior to the next annual stockholders' meeting, provided the director continues in service.

Industry Context

The grant of stock options to a non-employee director is a common practice in the biotechnology and pharmaceutical industry, serving as a form of compensation and an incentive to align director interests with shareholder value creation.

Comparison to Industry Standards

• This type of equity grant is a standard component of non-employee director compensation packages across publicly traded companies, particularly in growth-oriented sectors like biotechnology. While the specific number of options and exercise price are company-specific, the mechanism is consistent with industry benchmarks for attracting and retaining qualified board members.

Related Party Transactions

• The grant of 17,000 stock options to David J. Mack, a Director of BioXcel Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's long-term interests with shareholder value, potentially leading to more focused strategic decisions.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The stock options will vest according to the specified schedule, contingent on the director's continued service.
• Upon vesting, the director will have the right to exercise these options to purchase common stock at the exercise price of $2.01 per share until the expiration date.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, stock options, director compensation, insider transaction, Form 4